Fox Run Management L.L.C. Takes $542,000 Position in DENTSPLY SIRONA Inc. $XRAY

Fox Run Management L.L.C. purchased a new position in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 42,690 shares of the medical instruments supplier’s stock, valued at approximately $542,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of XRAY. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in DENTSPLY SIRONA in the first quarter valued at about $26,000. Parkside Financial Bank & Trust raised its stake in shares of DENTSPLY SIRONA by 620.6% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,715 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 1,477 shares during the period. True Wealth Design LLC lifted its holdings in shares of DENTSPLY SIRONA by 273.0% in the 2nd quarter. True Wealth Design LLC now owns 2,376 shares of the medical instruments supplier’s stock worth $38,000 after acquiring an additional 1,739 shares during the last quarter. Central Pacific Bank Trust Division boosted its position in shares of DENTSPLY SIRONA by 100.0% during the 3rd quarter. Central Pacific Bank Trust Division now owns 4,000 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 2,000 shares during the period. Finally, Versant Capital Management Inc increased its holdings in DENTSPLY SIRONA by 878.6% in the 3rd quarter. Versant Capital Management Inc now owns 4,883 shares of the medical instruments supplier’s stock valued at $62,000 after purchasing an additional 4,384 shares during the last quarter. 95.70% of the stock is currently owned by hedge funds and other institutional investors.

DENTSPLY SIRONA Price Performance

XRAY stock opened at $14.68 on Friday. The company has a debt-to-equity ratio of 1.36, a current ratio of 1.47 and a quick ratio of 0.99. The firm has a market capitalization of $2.93 billion, a P/E ratio of -4.89, a P/E/G ratio of 1.15 and a beta of 1.01. The business’s 50-day moving average is $12.42 and its two-hundred day moving average is $12.48. DENTSPLY SIRONA Inc. has a 1 year low of $9.85 and a 1 year high of $17.34.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings data on Thursday, February 26th. The medical instruments supplier reported $0.27 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). DENTSPLY SIRONA had a positive return on equity of 17.62% and a negative net margin of 16.25%.The company had revenue of $961.00 million for the quarter, compared to analyst estimates of $926.40 million. During the same period in the prior year, the firm posted $0.26 earnings per share. The business’s quarterly revenue was up 6.2% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Analysts anticipate that DENTSPLY SIRONA Inc. will post 1.84 earnings per share for the current fiscal year.

DENTSPLY SIRONA Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 9th. Shareholders of record on Friday, December 26th were given a $0.16 dividend. The ex-dividend date of this dividend was Friday, December 26th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 4.4%. DENTSPLY SIRONA’s dividend payout ratio is currently -14.48%.

Insider Buying and Selling at DENTSPLY SIRONA

In related news, Director Gregory T. Lucier sold 82,200 shares of the business’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $11.14, for a total transaction of $915,708.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.50% of the company’s stock.

Analyst Upgrades and Downgrades

XRAY has been the subject of several research analyst reports. Stifel Nicolaus set a $13.00 price target on DENTSPLY SIRONA in a research report on Thursday, November 6th. JPMorgan Chase & Co. decreased their target price on DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating on the stock in a research note on Friday, November 7th. Robert W. Baird lifted their target price on DENTSPLY SIRONA from $12.00 to $14.00 and gave the company a “neutral” rating in a research report on Friday. Mizuho boosted their price target on shares of DENTSPLY SIRONA from $13.00 to $14.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 20th. Finally, Bank of America raised shares of DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and increased their price target for the stock from $13.00 to $17.00 in a research report on Thursday, February 19th. Three analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $14.00.

Key Stories Impacting DENTSPLY SIRONA

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Company announced a $120 million restructuring to redirect annual savings into a “Return-to-Growth” plan (innovation, clinical and sales investment), eliminated the dividend and said it will redeploy capital toward debt paydown and share repurchases — a clear priority shift that drove buying interest. Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Top-line beat: Q4 net sales of $961M topped Street estimates and rose 6.2% year-over-year, a sign that demand trends held up despite cost issues. Dentsply Sirona’s Q4 CY2025 sales top estimates
• Neutral Sentiment: Analysts nudged price targets higher: Wells Fargo raised its target to $13 with an “equal weight” rating and Robert W. Baird raised its target to $14 with a “neutral” rating — upgrades that signal some analyst confidence but still leave implied downside vs. the current trading level. Analyst Price Target Moves (Benzinga) TickerReport: Baird PT Raise
• Neutral Sentiment: Earnings call and transcripts available for detail — useful for investors who want management commentary on the restructuring, capital allocation and product road map. Earnings Call Transcript
• Negative Sentiment: Reported adjusted EPS of $0.27 missed consensus by $0.01 and the quarter included a GAAP net loss of $146M driven by ~$144M of goodwill/intangible impairments — items that pressure near-term reported profitability. Earnings Miss Coverage (Zacks)
• Negative Sentiment: FY2026 revenue guidance of $3.5B–$3.6B sits below consensus (~$3.7B), signaling a softer top-line outlook even as adjusted EPS guidance of $1.40–$1.50 is roughly in line — the revenue gap is a downside catalyst to monitor. Company Outlook (GlobeNewswire)
• Negative Sentiment: Legal risk: Halper Sadeh LLC has opened a shareholder investigation into possible fiduciary breaches, which could create headline risk and distract management. Halper Sadeh Investigation Notice

DENTSPLY SIRONA Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.